Braltus with Zonda - Tiotropium
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
The professional's guide to product selection
The professional's guide to product selection
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Short-acting selective beta2 agonist.
For asthma
By mouth
Adult: 2.5 mg 3 times a day for 1–2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth.
By subcutaneous injection, or slow intravenous injection
Adult:250–500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.
By continuous intravenous infusion
Adult: 90–300 micrograms/hour for 8-10 hours, to be administered as a solution containing 3–5 micrograms/mL, high doses require close monitoring, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.
By inhalation of powder
Adult: 500 micrograms up to 4 times a day, for persistent symptoms.
By inhalation of nebulised solution
Adult: 5–10 mg 2–4 times a day, additional doses may be necessary in severe acute asthma.
For acute asthma
By subcutaneous injection, or by slow intravenous injection
• Child 2–14 years: 10 mcg/kg up to four times/day (maximum per dose 300 mcg)
• Child 15–17 years: 250–500 mcg up to four times/day
By continuous intravenous infusion
• Child: loading dose of 2–4 mcg/kg, then 1–10 mcg/kg/hour
For moderate, severe, or life-threatening acute asthma (given via oxygen-driven nebuliser if available)
• Child 1 month–4 years: 5 mg, repeated every 20–30 minutes or when required.
• Child 5–11 years: 5–10 mg, repeated every 20–30 minutes or when required.
• Over 12 years: 10 mg, repeated every 20–30 minutes or when required.
Exacerbation of reversible airway obstruction (including nocturnal asthma), prevention of exercise-induced bronchospasm
By inhalation of powder
• Child 5–17 years: 500 mcg up to four times/day
By mouth
• Child 1 month–6 years: 75 mcg/kg three times/day (maximum per dose 2.5 mg)
• Child 7–14 years: 2.5 mg 2–3 times daily
• Child 15–17 years: 2.5 mg three times/day, then increased if necessary to 5 mg three times/day.
Mucolytic to facilitate expectoration by reducing sputum viscosity.
• Adult: by inhalation of powder, over initiation dose (see product literature), then 400 mg, twice daily. The dose should be administered 5–15 minutes after a bronchodilator and before physiotherapy. The second daily dose should be taken 2–3 hours before bedtime.
Budelin Novoliser for prophylaxis of asthma by inhalation of powder
• Adult: 200–800 mcg twice daily
Budelin Novoliser as an alternative in mild to moderate asthma by inhalation of powder, for patients previously stabilised on a twice-daily dose
• Adult: 200–400 mcg once daily to be taken in the evening. Maximum per dose 800 mcg.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.